FDA Orders Juul Products to Be Removed from Retailers

Jul.01.2022
FDA Orders Juul Products to Be Removed from Retailers
FDA tried to order retailers to remove Juul products but a federal appeals court suspended the order, citing contrasting arguments.

If the U.S. Food and Drug Administration (FDA) has its way, one of the largest electronic cigarette retailers in the country may be forced out of business. Last Thursday, the FDA began sending letters to retailers ordering them to remove all Juul products from their shelves. The following day, a federal appeals court temporarily suspended the FDA's order, allowing Juul to continue selling its products while the court hears arguments from both sides.

 

The FDA is alleging that Juul has not provided "sufficient evidence regarding the toxicological characteristics of their products to demonstrate that their marketing is appropriate for protecting public health." In response, Juul released a statement calling the FDA's ban "arbitrary and capricious.

 

Is Juuling on the way out?

 

This week, health reporter for Time, Jamie Ducharme argued that the ban on Juul may not be the public health victory that people have imagined, and pointed out that "adult smokers also use Juul for smoking cessation - last week's decision was not a victory for them.

 

Tim Andrews from the US Tax Reform Organization also wrote in the Washington Post that taking Juul products off the market "will cut off a proven method that helps millions of smokers quit, leading to more smoking and more deaths." As evidence, Andrews cited comments "consistently finding e-cigarettes two to six times more effective than other cessation devices" and a study by Georgetown University Medical Center, which estimated that e-cigarettes could save the lives of up to 6.6 million Americans who would live at least 10 years longer.

 

Jonathan Foulds, a professor of public health sciences at Pennsylvania State University, agrees with this sentiment, stating on Twitter that "banning smoking from these life-saving exits because of 'potentially harmful chemicals' that may exude from some pods is a bit like locking the fire escape door because the steps might be slippery.

 

What's worse, Zule or cigars?

 

In his article for the Washington Post, Tim Andrews cited a "meta-analysis" of scientific research on e-cigarettes, commissioned by the UK government and "replicated by external medical institutions," which concluded that e-cigarettes are "95% safer than combustible tobacco." Bloomberg reporters Fiona Rutherford and Robert Langreth acknowledged that "some evidence suggests that e-cigarettes are a safer option than smoking," but claim that "there is not enough long-term data to draw a definitive conclusion." It is worth noting that Michael Bloomberg is a major funder of the campaign to ban flavored e-cigarette products.

 

From April 2019 to February 2020, the US experienced an outbreak of lung injuries related to the use of electronic cigarettes or vaping products, known as EVALI, resulting in 2,807 hospitalizations and 68 deaths. Of note, 82% of hospitalized patients reported using marijuana while only 14% reported nicotine use alone. The Centers for Disease Control and Prevention also found that many of the deaths or hospitalizations were linked to the use of unregulated black-market THC products in their vaping devices. In comparison, smoking is estimated to cause 480,000 deaths per year in the US.

 

However, electronic cigarettes may not be the healthy alternative that some supporters claim. The Johns Hopkins School of Medicine notes that electronic cigarettes have not been approved by the Food and Drug Administration as a smoking cessation device, and "recent research has found that the majority of people who intended to use electronic cigarettes to quit nicotine habit ended up continuing to use both traditional cigarettes and e-cigarettes.

 

Just think about the children!

 

In 2018, 30% of American high school students "reported having tried nicotine at least once in the past year," according to a cover story by Jamie Ducharme in TIME magazine in 2019. This is the largest increase in substance use in at least 44 years. The 2018 report by the National Academy of Sciences also showed that children who use e-cigarettes are more likely to try traditional cigarettes. Although the FDA's decision did not specifically address the relationship between Juul and youth e-cigarette use, as reported by the New York Times, "public health experts and legislators continue to express concern about the addition of nicotine to some e-cigarettes that remain on the market, including brands like PuffBar that offer fruit flavors that are attractive to young people.

 

However, the theory still remains debatable. Writing for a conservative independent women's forum, Lindsey Stroud argues that Juul does not encourage children to smoke. According to a public opinion survey, she wrote, "From 2019 to 2021, the usage of Juul products among 12th-grade students decreased by 46.9% in the past 30 days. Additionally, in 10th-grade students, the number of people using JUUL decreased by 75.3% during that time." The editorial board of The New York Daily News agreed, writing that Juul "has largely lost favor with teenage consumers" in recent years. However, all of this may just be a passing trend, like water vapor evaporating in the wind.

 

Source: The Week

 

This article contains excerpts or reprints of third-party information. The copyright of the reproduced information belongs to the original media and author.

 


Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Inside Nicotine-Pouch M&A Through Imperial's Yoik Deal: Latham, KPMG, PwC, Goldman Sachs and Morgan Stanley Form the Adviser Lineup
Inside Nicotine-Pouch M&A Through Imperial's Yoik Deal: Latham, KPMG, PwC, Goldman Sachs and Morgan Stanley Form the Adviser Lineup
Imperial Brands' acquisition of Swedish Helwit owner Yoik Group AB has highlighted the professional-services firms supporting cross-border oral nicotine M&A. Latham & Watkins and KPMG advised Imperial, while PwC and TM & Partners advised Yoik. KPMG also appeared on Imperial's acquisition of Black Buffalo earlier in 2026, while PwC played an extensive role in KT&G's acquisition of Swedish nicotine-pouch company Another Snus Factory. Imperial's public disclosures put the global modern oral nicotine delivery market at approximately £8.8 billion in retail sales and 23.5 billion pouches in 2024
Sep.20
UK HMRC Launches Vape Duty Stamps on October 1, Ushering in Supply-Chain Traceability as Chinese Exporters Face New Compliance Hurdles
UK HMRC Launches Vape Duty Stamps on October 1, Ushering in Supply-Chain Traceability as Chinese Exporters Face New Compliance Hurdles
HM Revenue & Customs put the UK's Vaping Products Duty and Vaping Duty Stamps Scheme into effect on October 1. All vaping liquids manufactured in or imported into the UK are now subject to duty at £2.20 per 10ml, regardless of nicotine content. The stamp regime will introduce digital functionality designed to provide traceability throughout the supply chain, with approved manufacturers, importers and warehousekeepers required to report product movements and retailers and consumers eventually able to scan stamps to verify authenticity. China exported $177 million of vape-related products to the UK in August, up 51.4% year over year, increasing the significance of the new compliance regime for China's Shenzhen-centered vape supply chain.
Regulations
Oct.04
UK-Listed Consumer Goods Group Supreme Sees Vape Duty as Potential Consolidation Opportunity, Holds FY27 Outlook
UK-Listed Consumer Goods Group Supreme Sees Vape Duty as Potential Consolidation Opportunity, Holds FY27 Outlook
UK-listed consumer goods group Supreme plc says it continues to expect FY27 trading to meet market expectations as the Vaping Products Duty takes effect on October 1, while maintaining a comparatively positive view of the new tax and compliance regime. Supreme has said the framework could increase compliance complexity for smaller operators and contribute to market consolidation, while its manufacturing, compliance and distribution scale may allow it to gain share. Its 88Vape brand will retain its value positioning.
Sep.18
Philippines BIR Steps Up Illicit Vape Enforcement Ahead of Christmas Shopping
Philippines BIR Steps Up Illicit Vape Enforcement Ahead of Christmas Shopping
The Philippines’ Bureau of Internal Revenue is intensifying enforcement against illicit vape and tobacco products ahead of the Christmas shopping season, directing regional and enforcement offices to strengthen monitoring of production sites, warehouses, distribution channels and retail outlets. The BIR destroyed 240,550 illicit vape products in August with an estimated tax liability of about PHP1.53 billion. A nationwide tax-compliance operation in July also inspected 3,590 businesses involved in tobacco and vapor products.
Regulations
Sep.17 by 2Firsts Perspectives
Trump Picks White House Health Policy Aide Heidi Overton to Lead FDA, Pending Senate Confirmation
Trump Picks White House Health Policy Aide Heidi Overton to Lead FDA, Pending Senate Confirmation
U.S. President Donald Trump has chosen White House health policy aide Heidi Overton to lead the Food and Drug Administration, Bloomberg reported, citing a person familiar with the matter. Overton currently works on health policy at the White House and previously held a senior role at the America First Policy Institute. If confirmed by the Senate, she would take over an FDA that has experienced months of senior-level turnover. The agency regulates products representing roughly one-fifth of U.S. consumer spending, including e-cigarettes, drugs, vaccines and much of the food supply.
News
Aug.19
As JUUL2 Wins FDA Authorization, Harm Reduction Journal Highlights the Role of Real-World Evidence in Nicotine Product Regulation
As JUUL2 Wins FDA Authorization, Harm Reduction Journal Highlights the Role of Real-World Evidence in Nicotine Product Regulation
A commentary published in the international open-access, peer-reviewed Harm Reduction Journal argues that randomized controlled trials remain central to evaluating smoking cessation efficacy but cannot alone capture real-world uptake, complete switching, longer-term use and population impact of non-combustible nicotine products such as e-cigarettes, heated tobacco and nicotine pouches. The authors frame impact as “reach × efficacy” and call for real-world evidence to complement RCTs. Three days after publication, the FDA authorized three JUUL2 products and highlighted complete switching among adult smokers in explaining its decision, providing a timely regulatory backdrop to the debate.
Sep.08